A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.

IF 4.2 3区 医学 Q1 DERMATOLOGY
Dermatology and Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-24 DOI:10.1007/s13555-025-01444-9
Emma L Myers, Donna A Culton
{"title":"A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.","authors":"Emma L Myers, Donna A Culton","doi":"10.1007/s13555-025-01444-9","DOIUrl":null,"url":null,"abstract":"<p><p>Pemphigoid diseases are a group of rare, chronic autoimmune blistering disorders (AIBD) characterized by subepidermal blister formation due to autoantibody-mediated targeting of structural components of the basement membrane zone (BMZ). This narrative review provides an updated overview of four key subtypes: bullous pemphigoid (BP), mucous membrane pemphigoid (MMP), linear IgA bullous dermatosis (LABD), and epidermolysis bullosa acquisita (EBA) with specific emphasis on disease associations that dermatologists should be aware of for comprehensive patient care. BP, the most common subepidermal blistering disorder, is frequently associated with neurological and cardiovascular comorbidities, while MMP primarily affects mucosal surfaces, often leading to significant scarring and functional impairment and can be associated with malignancy in certain subtypes. LABD and EBA are less common but can be linked with systemic autoimmune conditions such as inflammatory bowel disease (IBD). Shared challenges across these subtypes include difficulties in diagnosis due to overlapping clinical and histopathologic features, treatment-related complications from prolonged corticosteroid use, and the substantial impact on patients' quality of life. Advances in therapeutic strategies, including biologic agents such as rituximab and dupilumab, offer promising alternatives to traditional treatments, yet access to new targeted therapies remains a significant barrier. This review emphasizes the need for large-scale studies to better understand disease associations, the identification of biomarkers for personalized therapy, improved treatment options, and the implementation of multidisciplinary care approaches.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1755-1770"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01444-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pemphigoid diseases are a group of rare, chronic autoimmune blistering disorders (AIBD) characterized by subepidermal blister formation due to autoantibody-mediated targeting of structural components of the basement membrane zone (BMZ). This narrative review provides an updated overview of four key subtypes: bullous pemphigoid (BP), mucous membrane pemphigoid (MMP), linear IgA bullous dermatosis (LABD), and epidermolysis bullosa acquisita (EBA) with specific emphasis on disease associations that dermatologists should be aware of for comprehensive patient care. BP, the most common subepidermal blistering disorder, is frequently associated with neurological and cardiovascular comorbidities, while MMP primarily affects mucosal surfaces, often leading to significant scarring and functional impairment and can be associated with malignancy in certain subtypes. LABD and EBA are less common but can be linked with systemic autoimmune conditions such as inflammatory bowel disease (IBD). Shared challenges across these subtypes include difficulties in diagnosis due to overlapping clinical and histopathologic features, treatment-related complications from prolonged corticosteroid use, and the substantial impact on patients' quality of life. Advances in therapeutic strategies, including biologic agents such as rituximab and dupilumab, offer promising alternatives to traditional treatments, yet access to new targeted therapies remains a significant barrier. This review emphasizes the need for large-scale studies to better understand disease associations, the identification of biomarkers for personalized therapy, improved treatment options, and the implementation of multidisciplinary care approaches.

类天疱疮疾病的叙述性回顾:桥接关联,合并症和管理。
类天疱疮疾病是一种罕见的慢性自身免疫性起疱疾病(AIBD),其特征是由于自身抗体介导的基底膜带(BMZ)结构成分的靶向而形成皮下水疱。这篇叙述性综述提供了四种关键亚型的最新概述:大疱性类天疱疮(BP)、粘膜类天疱疮(MMP)、线性IgA大疱性皮肤病(LABD)和获得性大疱性表皮松解症(EBA),特别强调了皮肤病医生应该意识到的疾病关联,以进行全面的患者护理。BP是最常见的表皮下起疱性疾病,通常与神经系统和心血管合共病有关,而MMP主要影响粘膜表面,通常导致显着的疤痕和功能损害,并可与某些亚型的恶性肿瘤相关。LABD和EBA不太常见,但可能与系统性自身免疫性疾病如炎症性肠病(IBD)有关。这些亚型的共同挑战包括由于重叠的临床和组织病理学特征导致的诊断困难,长期使用皮质类固醇引起的治疗相关并发症,以及对患者生活质量的重大影响。包括利妥昔单抗和杜匹单抗等生物制剂在内的治疗策略的进步,为传统治疗提供了有希望的替代方案,但获得新的靶向治疗仍然是一个重大障碍。本综述强调需要进行大规模研究,以更好地了解疾病关联,识别个性化治疗的生物标志物,改进治疗方案,以及实施多学科治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Dermatology and Therapy
Dermatology and Therapy Medicine-Dermatology
CiteScore
6.00
自引率
8.80%
发文量
187
审稿时长
6 weeks
期刊介绍: Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信